| Home > Publications database > First in-vivo monitoring of helium-ion radiotherapy with secondary ions. |
| Journal Article | DKFZ-2026-00048 |
; ; ; ; ; ;
2026
Elsevier Science
Amsterdam [u.a.]
Abstract: Ion-beam radiotherapy offers steep dose gradients and high biological effectiveness required for the treatment of complex cancer cases. While the vast majority of ion-beam therapy centers today use protons and carbon ions, there is renewed interest in helium ions for their unique physical and radiobiological properties. All ion-beam treatments suffer from beam-range uncertainties mainly caused by potential changes of the patient morphology. In-vivo treatment monitoring with secondary ions could potentially provide feedback about the treatment quality that would allow a dose reduction in the healthy tissue or an escalation of the tumor dose.This work presents the first in-vivo monitoring of a helium-ion therapy patient treated for a solitary fibrous tumor. The method is based on the tracking of secondary ions that leave the patient as a natural by-product of ion-beam radiotherapy.The comparison of two measured secondary-ion distributions confirmed a high treatment reproducibility for the reported patient. However, significant differences between the two fractions were detected at the border of the skull base and the sinus sphenoidalis that could originate from potential inter-fractional cavity filling.The world's first in-vivo monitoring of innovative helium-ion therapy was performed successfully. In the future, the observed signals will need to be validated with patients that receive regular control CTs. Moreover, Monte Carlo simulations and phantom measurements will help to establish a robust link between changes in the secondary-ion distribution and clinically relevant dose changes.
|
The record appears in these collections: |